Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...
A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...
Forbes contributors publish independent expert analyses and insights. Dr. Omer Awan is a practicing physician who covers public health. A twice-yearly injection of a drug known as lenacapavir offered ...
The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One area that has been particularly hard hit has been research, prevention, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results